Medicus Pharma Ltd., was incorporated on April 30, 2008 under the laws of the province of Ontario, Canada. They are a biotechnology and life sciences company focused on accelerating clinical development programs for new and disruptive therapeutic assets. Currently, they are developing a product, SkinJectTM, for the treatment of basal cell carcinoma. Through its wholly-owned subsidiary SkinJect, Inc., they are focused on developing their licensed drug-device portfolio products for the treatment of non-lanoma skin cancer using novel dissolvable microneedle arrays. Their joint product candidate is doxorubicin tip-loaded D-MNA submitted to the U.S. Food and Drug Administration (" FDA ") under a new drug research application, regulated by the Center for Drug Evaluation and Registry in Oncology (CDER).